Deciding between two pharmaceutical giants requires a close look at pipeline growth and patent longevity. For investors in 2026, comparing AbbVie (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) reveals two very different paths to potential long-term returns. <\/p>\n
AbbVie has successfully pivoted from its Humira era toward new immunology leaders, while Pfizer is navigating a post-pandemic transition by aggressively acquiring new oncology and metabolic assets. Both companies offer significant dividends, yet they face distinct regulatory hurdles and patent expirations that will shape their trajectories for the remainder of the decade. <\/p>\n
The case for AbbVie <\/p>\n
AbbVie is a research-driven biopharmaceutical company focusing on immunology, oncology, and aesthetics within the broader realm of pharmaceutical stocks<\/a>. The company relies on three major wholesale distributors, McKesson Corp (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR), for nearly all of its pharmaceutical sales in the United States. Customer concentration like this adds a layer of risk to the business since a disruption with any one partner could affect distribution. <\/p>\n In its latest annual report, filed for FY 2025, the company reported that revenue reached about $61.2 billion. This represents revenue growth of approximately 8.6% compared to the prior year. Despite the rising sales, AbbVie recorded net income close to $4.3 billion, reflecting a net margin of about 7%. <\/p>\n As of its December 2025 balance sheet, AbbVie reported a debt-to-equity ratio of negative 21.1x, which indicates that total liabilities exceed shareholder equity. Its so-called current ratio, measuring a company’s ability to cover its short-term debts with short-term assets, stands at approximately 0.7x. During the same period, the company generated free cash flow of nearly $17.8 billion, which is the cash a company generates from its operations minus any capital expenditures. <\/p>\n The case for Pfizer <\/p>\n Pfizer operates as a global biopharmaceutical company that develops and manufactures a wide range of medicines and vaccines. Its business strategy emphasizes innovation in oncology and vaccines, with significant revenue derived from established products like Eliquis. The company also engages in national immunization programs and maintains agreements with the U.S. government for certain drug pricing concessions. <\/p>\n In FY 2025, Pfizer reported that its revenue reached approximately $62.6 billion, reflecting a slight revenue decline of around 1.6%. Despite this slight dip, the company achieved net income of roughly $7.8 billion during the period. This resulted in a net margin of approximately 12.4%, showing that the company remains highly profitable as it integrates new business lines. <\/p>\n As of its December 2025 balance sheet, Pfizer maintains a debt-to-equity ratio of approximately 0.8x, comparing total debt to shareholder equity to gauge financial leverage. Its current ratio, a measure of short-term liquidity, is roughly 1.2x. During FY 2025, Pfizer generated free cash flow of approximately $9.1 billion, representing the cash remaining after the company pays for its operations and capital investments. <\/p>\n Risk profile comparison <\/p>\n AbbVie faces significant revenue concentration from its primary immunology products, Skyrizi and Rinvoq. The expiration of patents or successful legal challenges to these biologics could lead to competition from biosimilar manufacturers. Furthermore, the Inflation Reduction Act allows the government to set prices for high-expenditure drugs, and several AbbVie products have already been selected for this process. <\/p>\n Pfizer is navigating a revenue cliff caused by declining demand for COVID-19 products and upcoming patent expirations for key drugs. To counter this, the company must successfully integrate major acquisitions such as Seagen and Metsera to replenish its product pipeline. Pfizer also remains subject to global economic risks, including currency volatility and pricing pressures from international government regulations. <\/p>\n Valuation comparison <\/p>\n Pfizer trades at a lower Forward P\/E<\/a> and P\/S ratio than AbbVie, comparing future earnings estimates and sales over the past twelve months. <\/p>\n Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers. <\/p>\n Which stock would I buy in 2026? <\/p>\n Pfizer isn’t a hot growth stock, but it’s also one of the giants of the pharmaceutical industry. <\/p>\n The company had a post-COVID letdown of sorts, as pandemic-related demand ebbed, but the business has been flexing its might this year. In its first quarter of this year, Pfizer beat Wall Street analysts’ expectations on sales and net income. That is partly because Pfizer has been buying growth — it recently acquired oncology specialist Seagen and posted 20% growth in that business’s products. <\/p>\n Pfizer is also allocating significant resources to new drug development, with 20 drug development starts scheduled for 2026 and eight data readouts expected, which report on the progress of treatments in development. After falling behind in the GLP-1 weight-loss drug market, Pfizer is also making strides toward becoming a competitor, with very positive Phase II (of III) trial results for an injectable GLP-1 reported earlier this year. <\/p>\n AbbVie has a drug pipeline that some on Wall Street believe could include blockbusters (more than $1 billion in lifetime revenue) for treating schizophrenia, Parkinson’s disease, psychosis from Alzheimer’s, and certain solid tumors. <\/p>\n The company is also buying itself growth with its recent acquisition of ApogeeTherapeutics. AbbVie’s two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that an FDA decision on a Parkinson’s treatment later this year will bode well for the company. The business is expected to see notable growth in net income this year, to $14.6 billion from $4.2 billion. Sales should grow to $67.2 billion. <\/p>\n With more than $6 billion in cash, a forward price-to-earnings ratio of a bargain basement 9.6, and an attractive yield of 6% based on its recent price of $28.50, Pfizer seems too discounted to overlook, despite an excellent case for AbbVie. <\/p>\n Should you buy stock in AbbVie right now? <\/p>\n Before you buy stock in AbbVie, consider this: <\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. <\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $386,781!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,379,943!* <\/p>\n Now, it’s worth noting Stock Advisor’s total average return is 936% \u2014 a market-crushing outperformance compared to 213% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. <\/p>\n See the 10 stocks \u00bb<\/a> <\/p>\n *Stock Advisor returns as of September 25, 2026. <\/p>\n Brendan Coffey<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy<\/a>. <\/p>\n